Ivabradine
Read the leaflet carefully before taking the medicine, as it contains important information for the patient.
Ivabradine Viatris (ivabradine) is a heart medicine used to treat:
About stable angina pectoris (commonly referred to as "angina"):
Stable angina pectoris is a heart disease that occurs when the heart muscle does not receive enough oxygen. This disease usually appears in people between 40 and 50 years of age. The most common symptom of angina pectoris is chest pain or discomfort.
Angina pectoris occurs more frequently when the heart works faster, for example, during exercise, emotions, cold, or after eating. In people with angina pectoris, an increase in heart rate causes chest pain.
About chronic heart failure:
Chronic heart failure is a heart disease that occurs when the heart cannot pump enough blood to the entire body. The most common symptoms of heart failure are shortness of breath, fatigue, tiredness, and swelling of the ankles.
How does Ivabradine Viatris work?
Ivabradine Viatris works mainly by reducing the heart rate by a few beats per minute. This leads to a reduction in the oxygen demand of the heart muscle, especially in situations where an angina attack is more likely to occur. In this way, Ivabradine Viatris helps control and reduce the number of angina attacks.
Additionally, since a reduced heart rate has a negative effect on heart function and survival in patients with chronic heart failure, the specific action of ivabradine, which reduces the heart rate, helps improve heart function and survival in these patients.
Before starting treatment with Ivabradine Viatris, discuss with your doctor or pharmacist:
In case of any of the above situations, inform your doctor before taking or during treatment with Ivabradine Viatris.
Ivabradine Viatris is not intended for use in children and adolescents under 18 years of age.
Tell your doctor or pharmacist about all medicines you are taking or have recently taken, as well as any medicines you plan to take.
Inform your doctor about taking any of the following medicines, as it may be necessary to modify the dose of Ivabradine Viatris or closely monitor the course of treatment:
Avoid drinking grapefruit juice while taking Ivabradine Viatris.
Do not take Ivabradine Viatris during pregnancy or if you are planning to have a baby (see "When not to take Ivabradine Viatris").
Inform your doctor if you become pregnant while taking Ivabradine Viatris.
Women of childbearing age should not take Ivabradine Viatris unless they use effective contraception (see "When not to take Ivabradine Viatris").
Do not take Ivabradine Viatris during breastfeeding (see "When not to take Ivabradine Viatris"). If you are breastfeeding or plan to breastfeed, consult your doctor, as breastfeeding should be stopped if you are taking Ivabradine Viatris.
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Ivabradine Viatris may cause transient vision disturbances (temporary sensations of bright light in the field of vision, see "Possible side effects"). If they occur, be cautious while driving or operating machinery, especially in situations where there may be sudden changes in lighting intensity, especially when driving at night.
If you have been told that you have an intolerance to some sugars, contact your doctor before taking this medicine.
This medicine contains less than 1 mmol of sodium (23 mg) per tablet, which is considered "sodium-free".
Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, ask your doctor or pharmacist.
Ivabradine Viatris should be taken with food.
The 5 mg tablet can be divided into equal doses.
If you are being treated for stable angina pectoris
The initial dose should not be more than one 5 mg tablet of Ivabradine Viatris twice a day. If you still have symptoms of angina and tolerate the 5 mg dose twice a day well, the dose may be increased. The maintenance dose should not be more than 7.5 mg twice a day. Your doctor will prescribe the right dose for you. The recommended dose is one tablet in the morning and one tablet in the evening. In some cases (e.g., if you are elderly), your doctor may prescribe half the dose, i.e., half a 5 mg tablet of Ivabradine Viatris 5 mg (which corresponds to 2.5 mg of ivabradine) in the morning and half a 5 mg tablet in the evening.
If you are being treated for chronic heart failure
The recommended initial dose is one 5 mg tablet of Ivabradine Viatris twice a day, which can be increased to one 7.5 mg tablet of Ivabradine Viatris twice a day if necessary. Your doctor will determine the right dose for you. The usual dose is one tablet in the morning and one tablet in the evening. In some cases (e.g., if you are elderly), your doctor may prescribe half the dose, i.e., half a 5 mg tablet of Ivabradine Viatris 5 mg (which corresponds to 2.5 mg of ivabradine) in the morning and half a 5 mg tablet in the evening.
After taking a higher dose of Ivabradine Viatris, shortness of breath or fatigue may occur, as the heart rate slows down too much. In this case, contact your doctor immediately.
If you miss a dose of Ivabradine Viatris, take the next dose at the usual time.
Do not take a double dose to make up for the missed dose.
[For calendar blister packs] The calendar printed on the blister pack containing the tablets will help you remember when you last took a tablet of Ivabradine Viatris.
Since treatment for angina or chronic heart failure is usually long-term, do not stop taking this medicine without consulting your doctor.
If you feel that the effect of Ivabradine Viatris is too strong or too weak, consult your doctor or pharmacist.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, Ivabradine Viatris can cause side effects, although not everybody gets them.
The most common side effects of this medicine are dose-dependent and are related to its mechanism of action:
Very common (may affect more than 1 in 10 people):
Visual disturbances (temporary sensations of bright light, most often caused by sudden changes in lighting intensity). These disturbances are also described as auras, colored flashes, split images, or multiple images. They usually appear during the first two months of treatment and may recur and disappear during or after treatment.
Common (may affect up to 1 in 10 people):
Changes in heart rate (symptoms of slowed heart rate). Symptoms occur especially during the first 2 to 3 months after starting treatment.
Other side effects have also been reported:
Common (may affect up to 1 in 10 people):
Irregular, rapid heartbeats, unusual sensations of heartbeat, uncontrolled high blood pressure, headaches, dizziness, and blurred vision (blurred vision).
Uncommon (may affect up to 1 in 100 people):
Palpitations and extra heartbeats, nausea, constipation, diarrhea, abdominal pain, feeling of spinning (dizziness of labyrinthine origin), breathing difficulties (shortness of breath), muscle cramps, and changes in laboratory parameters: high levels of uric acid in the blood, increased eosinophil count in the blood (a type of white blood cell), and increased creatinine levels in the blood (a muscle breakdown product), rash, angioedema (such as swollen face, swollen tongue, or throat, difficulty breathing or swallowing), low blood pressure, fainting, feeling of tiredness, feeling of weakness, abnormal ECG recording, double vision, impaired vision.
Rare (may affect up to 1 in 1,000 people):
Hives, itching, flushing.
Very rare (may affect up to 1 in 10,000 people):
Irregular heartbeat.
If you experience any side effects, including those not listed in this leaflet, tell your doctor or pharmacist. Side effects can be reported directly to the Department of Drug Adverse Reaction Monitoring, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the carton and blister after "EXP". The expiry date refers to the last day of the month stated.
There are no special precautions for storing this medicine.
Do not use this medicine for more than 6 months after opening the HDPE container.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
What Ivabradine Viatris looks like and what the pack contains
Ivabradine Viatris, 5 mg, are yellow, round, coated tablets with "5" engraved on one side and a score line on the other side. The tablet can be divided into equal doses.
Ivabradine Viatris, 7.5 mg, are orange-yellow, round, biconvex, coated tablets with "7.5" engraved on one side.
Tablets are available in blisters (OPA/Aluminum/PVC/Aluminum; PVC/PE/PVDC/Aluminum) containing 56 or 56x1 coated tablets.
Not all pack sizes may be marketed.
Viatris Limited, Damastown Industrial Park, Mulhuddart, Dublin 15, DUBLIN, Ireland
HBM Pharma s.r.o., Sklabinská 30, 03680 Martin, Slovakia, Delorbis Pharmaceuticals Ltd, 17, Athinon Street, Ergates Industrial Area, 2643 Ergates, Lefkosia, Cyprus. For more information on this medicine and its names in the Member States of the European Economic Area, contact the local representative of the marketing authorization holder:
Tel: +48 22 546 64 00
Date of last revision of the leaflet:June 2024
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.